León-Letelier, R.A.; Abdel Sater, A.H.; Chen, Y.; Park, S.; Wu, R.; Irajizad, E.; Dennison, J.B.; Katayama, H.; Vykoukal, J.V.; Hanash, S.;
et al. Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis. Cancers 2023, 15, 834.
https://doi.org/10.3390/cancers15030834
AMA Style
León-Letelier RA, Abdel Sater AH, Chen Y, Park S, Wu R, Irajizad E, Dennison JB, Katayama H, Vykoukal JV, Hanash S,
et al. Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis. Cancers. 2023; 15(3):834.
https://doi.org/10.3390/cancers15030834
Chicago/Turabian Style
León-Letelier, Ricardo A., Ali H. Abdel Sater, Yihui Chen, Soyoung Park, Ranran Wu, Ehsan Irajizad, Jennifer B. Dennison, Hiroyuki Katayama, Jody V. Vykoukal, Samir Hanash,
and et al. 2023. "Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis" Cancers 15, no. 3: 834.
https://doi.org/10.3390/cancers15030834
APA Style
León-Letelier, R. A., Abdel Sater, A. H., Chen, Y., Park, S., Wu, R., Irajizad, E., Dennison, J. B., Katayama, H., Vykoukal, J. V., Hanash, S., Ostrin, E. J., & Fahrmann, J. F.
(2023). Kynureninase Upregulation Is a Prominent Feature of NFR2-Activated Cancers and Is Associated with Tumor Immunosuppression and Poor Prognosis. Cancers, 15(3), 834.
https://doi.org/10.3390/cancers15030834
